Lexicon Pharmaceuticals Inc (LXRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.05 (+0.74%), Market cap $1.03B, 52-week low–high $0.53 ~ $2.44.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an or
Financial statements, price targets, institutional (13F) holdings and related news for Lexicon Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Lexicon Pharmaceuticals Inc trades at $2.05 (+0.74%). Real-time quotes and charts are available on BlackAll Trade.
Lexicon Pharmaceuticals Inc has a market cap of about $1.03B.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company deve